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Abstract
Glioblastoma multiforme is one of the most aggressive tumors of the central  
nervous system. The current standard-of-care includes maximal resection  
followed by chemotherapy, radiation and more recently, tumor treating fields 
(TTFs). Despite this multimodal approach, glioblastoma remains refractory to 
therapy. Glioblastoma resistance, recurrence and malignancy are believed to be 
driven by a subpopulation of glioma stem cells (GSCs) within the tumor bulk which 
are characterized by the retention of self-renewal potential as well as the capac-
ity to recapitulate tumor heterogeneity. Within the dynamic intratumoral niche, 
GSCs demonstrate a high degree of cellular plasticity, reversibly interconverting 
between stem-like states and more differentiated states as a result of environmental 
cues/signaling fluctuations. Such plastic adaptive properties are mostly driven by 
multiple dynamic, reversible epigenetic modifications. We posit that reversible 
post-transcriptional methylation of RNA transcripts at the m6A position may be one 
such regulatory mechanism employed by GSCs to efficiently maintain plasticity and 
adaptive phenotypic transitions. In this section, we discuss the concept of cellular 
plasticity, introduce dynamic m6a epitranscriptomic mechanisms as potential key 
regulators of GSC plasticity and finally propose epigenetic based therapeutics as a 
mean of attenuating glioblastoma plasticity to improve patient outcome.
Keywords: glioma stem cell, plasticity, epigenetic landscape, epitranscriptome, 
cellular states, glioblastoma
1. Introduction
Glioblastoma is one of the most lethal malignant tumors of the central nervous 
system. Its treatment involves maximal resection followed by chemotherapy, radia-
tion and tumor treating fields [1]. Despite this multimodal approach, GBM remains 
uniformly lethal, with a median survival of 15 to 16 months [1]. Histologically, 
GBM presents as a heterogenous mass with multifocal necrosis, hypervasculariza-
tion, hemorrhage, pleiomorphic cells with notable mitotic activity and pseudo-
palisading nuclei [2, 3]. Recent advances in whole genome sequencing allowed for 
better GBM characterization to compliment current medical knowledge.
The Cancer Genome Atlas (TCGA) initiative generated DNA, RNA and meth-
ylation sequencing data on multiple GBMs and lower grade gliomas [4], shedding 
light onto GBM specific structural, mutational and methylation alterations. It was 
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shown that NF1, IDH, PDGFRA and PARK2 were mutated and that AKT3 and 
EGFR were amplified in GBMs [5, 6]. Additionally, the vast majority of GBMs were 
shown to activate the RB, p53 and RTK/RAS/PI3K pathways [5]. Using tumor gene 
expression signatures, patients could be categorized into discrete subtypes, namely 
mesenchymal, proneural and classical [6]. However, subtyping did not directly 
relate to long term survival [7]. Tendencies towards survival were only observed 
when the data was restricted to patients with lowest simplicity score [7].
The TCGA derived data supplied useful information, but it simultaneously 
raised new questions. First, it was noted that 8% of the samples did not discretely 
fit within defined TCGA subtypes, but instead scored for multiple subtypes [6–8]. 
Second, tumors were shown to undergo subtype switching following recurrence 
[9]. Third, even with low mutational burden, GBM exhibited significant intra and 
inter tumoral heterogeneity. GBM’s aggressiveness and recurrence is believed to be 
driven by a small subpopulation of stem like cells within the tumor niche [10–13]. 
These cells, generally referred to as glioma stem cells (GSCs), possess the ability to 
self-renew and can fully recapitulate the tumor bulk with fidelity to parental tissue 
properties following xenotransplantation [14]. Recent developments have helped to 
catapult GSCs at the nexus of GBM tumorigenesis. It has been shown that the adult 
human brain is not an entirely post-mitotic tissue and to possess specific regions 
with an enrichment for cells with stem like properties or neural stem cells (NSCs) 
[14, 15]. Interestingly, NSC markers such as CD133 and Nestin are frequently 
expressed in GSCs [16]. Such homology raised questions on GSCs relation to NSCs. 
Thus, “the cell of origin” theory emerged. The theory posited that GSCs, which 
are mutated NSCs are the cells of origin of GBM. Spatial studies demonstrated 
that GBMs exhibited a growth bias for the subventricular zone (SVZ), a region 
known to be enriched with NSCs [14]. Furthermore, multiple studies showed that 
de novo GBM tumorigenesis could be achieved by inducing tumor initiating muta-
tions within the SVZ [8]. Together, these findings cemented GSCs as initiators and 
drivers of GBM, hence placing them center stage as key targets in GBM therapy. 
However, most therapies targeted at GSC continue to fail, likely due to GSCs’ high 
adaptability potential and tendency to continuously fuel tumor niche dynamic 
heterogeneity by undergoing reversible multilineage differentiation.
The aforementioned complex cell dynamics likely rely on coordinated genetic 
and epigenetic processes. Here, we focus on epigenetic processes, more specifically 
post transcriptional chemical decorum on mRNA adenosine or mRNA m6A. This 
chemical modification has widely been explored in dynamic processes ranging from 
neurogenesis, memory formation to various pathophysiological processes including 
cancers [17–19]. We discuss what is known at the m6A/plasticity interface in GBM 
and finally postulate/propose ways in which epitranscritpomics can function as a 
predictive or therapeutic tool to affect clinical outcome.
2. Cellular plasticity in glioblastoma
GBM exhibits a high degree of intertumoral and intratumoral heterogeneity. 
Such heterogeneity is sustained by constant, dynamic interconversion between 
cellular states. Differentiated glioma stem cells (DGCs) undergo spontaneous 
de-differentiation to primordial states or back to GSCs and vice versa in response 
to fluctuating microenvironmental cues [20–23]. It is likely that this tumor hijacks 
highly conserved genetic and epigenetic programming generally associated with 
stemness multipotency and early embryonic development in order to rapidly adapt 
to and evade various therapeutic strategies. Therefore, glioma cancer cells leverage 
such plasticity to maintain an adaptive, shifting cell state population equilibrium 
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that is not amenable to therapy. For example, radiotherapy and temozolamide 
induce adaptive, spontaneous de-differentiation of DGCs to GSCs, thereby increas-
ing and replenishing the cancer stem pool [24]. Such a shift in cell population 
distribution towards increased stemness forcibly translates to a more refractory 
tumor organ.
Recent work shows that GSCs clones are able to readily undergo reversal pheno-
typic transition between clonal populations [21]. The authors also demonstrated the 
reversible nature of the cellular equilibria assumed by GSCs in the face of hypoxia 
as the cells return to a naïve, pre-hypoxia exposure following normoxia [21]. In 
a fashion reminiscent of the Waddington landscape, GSCs inherently possess a 
high cellular plasticity potential, thus exist in thermodynamically poise cellular 
states, and can adaptively differentiate to assume multiple population equilibria in 
response to external perturbation [21]. These rapid processes entail myriad cellular 
epigenetic regulatory mechanisms, one of which is the dynamic regulation of m6A.
3. The epitranscriptome in glioblastoma
Currently, there are over 170 possible chemical modifications on RNA species 
[25]. The majority occurs on highly abundant non-coding RNA species such as 
rRNAs, tRNAs and snRNAs and consequently influence RNA stability and RNA 
secondary/tertiary structure [26]. Most of these modifications are challenging to 
study in mRNA due to their sparsity and relatively higher abundance in rRNA and 
tRNA, hence imposing a detection problem in coding RNA [25, 27]. Conversely, 
N6-methyladenosine (m6A) is highly enriched in mRNA, but sparse in rRNA and 
absent in tRNAs. The occurrence of m6A on mRNA and its effector role on mRNA 
stability were established in the 1970s [28, 29]. Since, a set of complexes responsi-
ble for 1) placement of m6A on transcripts (m6A methyltransferases or “writers”)  
2) removal of m6A (m6A demethylases or “erasers” 3) “interpretation” or effec-
tor function of m6A marks (readers) have been identified. Readers include the 
YTH domain containing YTHDF1-F3 and YTHDC1-C2. YTHDC1 and YTHDC2 
bind methylated nuclear transcript, while YTHDF1, YTHDF2 and YTHDF3 bind 
methylated cytoplasmic transcript [30–35]. Methyltransferase-like 3 (METTL3), 
methyltransferase-like 14 (METTL14) and Wilm’s-tumor-1-associated protein 
(WTAP) form a multimeric methyltransferase complex responsible for m6A mark 
transcript placement [36–38]. The removal of m6A is mediated by the fat mass-
and-obesity-associated protein (FTO) and alkylation repair homolog protein 
5 (ALKBH5) [39, 40]. The discovery of these m6A RNA demethylases implied 
possible reversibility or dynamism inherent to the epitranscriptome. Once placed 
on transcripts, m6A has been shown to modulate mRNA stability, splicing and 
translation and thus ultimately influence gene expression kinetics and outcome 
[32–34]. Following the refinement of m6A detection techniques, m6A has been 
widely studied in physiologic processes, such as early development, and in patho-
physiologic processes, ranging from psychiatric disorders to cancers. Here, we 
focus our attention to the glioblastoma/m6A interface as it pertains to plasticity.
3.1 m6A writers in glioblastoma
The most common way the m6A code has been probed in GBM is via enzymatic 
inhibition or transcript level perturbation of the m6A machinery. The majority of 
works on the role of writers in GBM suggest an oncogenic role for METTL3/METTL14. 
The methyltransferase METTL3 has been shown to be essential for sustenance of 
GSCs, radioresistance and GBM oncogenic signaling [41–44]. Yet, METTL3 and 
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METTL14 have been shown in an overexpression-based study to reduce GSCs tumori-
genicity and stemness potential, suggesting a potential tumor suppressive function 
[45]. The reasons for these discrepancies pertaining to m6A writers are unclear and 
necessitate additional clarifying studies. Ultimately, these results could possibly 
reflect GBM heterogeneity/complexity and hence dissuade against generalizations on 
m6A in GBM.
3.2 m6A erasers in glioblastoma
So far, the known m6A erasers exhibit oncogenic tendencies in GBM. Inhibition 
of FTO demethylase activity has been shown by two independent groups to inhibit 
stemness propensity in GSCs [45, 46]. In another study, ALKBH5 was shown to be 
highly expressed in GSCs and functioned to promote tumorigenicity via FOXM1 
transcript stabilization [47].
3.3 m6A readers in glioblastoma
The functional role of the YTH readers in GBM had been unknown until very 
recently. Two recent studies show that YTHFD2 promotes GBM aggressiveness, 
albeit through different proposed mechanisms [48, 49]. One study finds that 
YTHDF2, though previously shown to destabilize transcripts, does however 
stabilize MYC and VEGFA transcripts in GSCs in an m6A-dependent manner [48]. 
The other study shows that the EGFR/SRC/ERK pathway functions to stabilize 
YTHDF2 via protein phosphorylation and YTHDF2 consequently destabilizes 
transcripts implicated in cholesterol dysregulation and invasive GBM growth [49]. 
Again, these differences may suggest context dependence given GBM’s high levels 
of heterogeneity and plasticity.
Summary of the role of various components of the m6A RNA methylation 
machinery in glioblastoma is presented in Figure 1. Though hinting at plasticity, 
most of these studies do not explicitly determine m6A dynamics in the context of 
GBM cell state transition.
3.4 Role of m6A in cellular plasticity in glioblastoma
Recent findings in neuroscience pertaining to neurogenesis and gliogenesis 
emphasize the centrality of m6A in dictating cell fate/state specification and plas-
ticity events during early brain development. Stem cells of the nervous system, 
known as radial glia cells (RGCs) or neural progenitor cells, which are responsible 
for neurogenesis and gliogenesis, show m6A dependency [50]. As per one study, 
conditional KO of Mettl3/Mettl14 in embryonic mouse brain resulted in premature 
activation of later stage differentiation specific transcripts that are normally kept 
low in RGCs [50]. Consequently, m6A depleted RGCs could not undergo appropri-
ate multilineage differentiation and expectedly formed abnormal brain tissue [50]. 
Another study shows that the process of glial specification relies on m6A [51]. 
Depletion of Prrc2a, which is a gene coding for the Olig2 stabilizing m6A reader 
PRRC2A, results in hypomethylation and cognitive defect secondary to Olig2 tran-
scription factor destabilization [51]. These studies demonstrate the key role of the 
m6A code in driving cell fate specification, differentiation and hence plasticity via 
transcriptional regulation during neurogenesis. From these data, a corollary can be 
drawn that GSCs, which are mutated NSCs, could exhibit significant m6A depen-
dence during differentiation, de-differentiation, tumorigenesis and in response 
to external perturbation such as radiation and chemotherapy. However, this m6A/
plasticity axis in GSCs and GBM niche remains poorly understood. Recently, we 
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performed an integrated whole genome meRIP-seq, RNA-seq and ribo-seq analysis 
in three patient-derived GSCs and differentiated progenies [52]. This allowed for the 
interrogation of transcriptional, epitranscriptional and translational kinetics during 
Figure 1. 
Summary of key findings for the role of the various components of the m6A machinery in glioblastoma.
Figure 2. 
miRNAs direct FTO/AGO1/ILF3 complex on RRACH m6A motifs to induce RNA demethylation and increase 
in nascent translation during the transition of GSCs to differentiated progenies.
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cell state transition [52]. In the study, we deliberately avoid m6A machinery pertur-
bation and simply attempt to unravel what happens in one of the most basic process 
of GSCs plasticity (differentiation) in the context of m6A dynamics. We discovered 
that a set of clinically relevant transcripts which experience the greatest increase in 
translation efficiency during differentiation also show significant loss in m6A peaks. 
This pattern occurred independently of glioblastoma subtypes. We found that these 
common, highly translated transcripts during GSC differentiation share a consensus 
m6A motif (the RRACH motif) that overlap a specific set of miRNA sequences. In 
addition, we discovered a corresponding striking increase in expression of some 
of these miRNAs with GSC differentiation. Subsequently, we asked whether these 
findings implicate miRNA at the m6A/translation interface during differentiation. 
Through a series of mechanistic studies, we propose a mechanism whereby miRNAs 
can facilitate the formation of a transcript stabilizing FTO-ILF3-AGO1 complex. This 
results in more efficient association with the ribosome, thus promoting an increase 
in nascent translation (Figure 2).
4. The epitranscriptome as a therapeutic target in glioblastoma
Though in its infancy, the field of epitranscriptomics holds significant prom-
ise for the development of novel epigenetic therapies against GBM. Currently, 
strategies for targeting the m6A machinery in glioblastoma are directed at the 
inhibition of enzymatic activity [45, 46]. Recently, targeting of the m6A erasers as 
well as YTHDF2 have shown some encouraging results for GBM treatment [48]. 
Specifically, it was shown that high levels of YTHDF2 correlate with increased 
sensitivity to Linsitinib, an inhibitor of the YTHDF2 downstream effector 
IGFBP3 [48].
Another emerging avenue is the fusion of m6A machinery components to RNA 
targeting CRISPR complexes [53, 54]. The deployment of the m6A machinery-
CRISPR complex can allow for the specific activation or deactivation of specific 
transcripts via m6A manipulation [56, 57]. The safe and reversible target specific 
stabilization or destabilization of coding and/or non-coding RNA species represents 
an exciting frontier in the development of RNA based therapeutics.
However, these findings leave more avenues for inquiry. For example, what role 
does the epitrancriptome play in de-differentiation of GSCs, in therapeutic eva-
sion and in microstate transitions of GSCs and differentiated progenies? Are there 
specific “m6A codes” associated with specific cellular microstates? And how do m6A 
processes work in synergy with other cellular machineries such as miRNAs, long 
non-coding RNAs, or well established GBM tumor promoting/suppressing signaling 
pathways to maintain plasticity? Are m6A dynamics driving or secondary events in 
GBM microstate transitions? Evidently, more work needs to be done to probe the 
m6A/plasticity interface in GSCs in order to aid in the discovery of novel epigenetic 
therapies targeting GSC plasticity.
5. A systems approach towards an epigenetic landscape in glioblastoma
Recent advancements in single cell RNA sequencing, which include integrated 
single cell multi-omics analysis, as well as the application of novel algorithms such 
as pseudotime and RNA velocity have allowed for better characterization of the 
dynamics within the heterogenous GBM tumor niche [21, 55, 56]. Initial single 
cell analysis demonstrated that GBM cancer cells exist in a cell state continuum 
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with polarization towards specific fates [55]. Additionally, projection of single cell 
transcriptomics onto a fetal neurodevelopmental roadmap identified previously 
unidentified glioma stem cell properties and established GSC at the apex of the glio-
blastoma tumor hierarchy [21]. These rapidly cycling apical progenitor cancer stem 
cells were found to have a transcriptional profile that overlapped glial progenitor 
cells [21]. Furthermore, RNA velocity analysis showed apical stem cell transcrip-
tional adjacency and velocity vector flow towards the more differentiated tumor cell 
lineages [21]. Collectively, such findings hint at clear plasticity/fluidity within the 
tumor. The integration of epitranscritpomics with single cell multi-omics tech-
nology could help unveil the yet undiscovered mechanism of how dynamic m6A 
changes play a role in driving plasticity within the tumor niche.
It has been posited that a stem cell may exist at a high or even maximal cellular 
state of entropy and can readily shift states in the face of perturbation [57]. Our 
view of the cancer stem cell state in glioblastoma agrees with the theory put forward 
20 years ago [58] suggesting that the glioma stem cell is a cellular state or function 
rather than an entity and this state of maximum cellular entropy is influenced by 
the constantly adaptable microenvironment of the tumor. In this context, distribu-
tion of species would represent heterogeneity, which single cell RNA sequencing 
adequately captures. Quantum states would equate probability distribution of 
discrete cell state occupancy bias. In other words, if we looked across a large set of 
samples and performed, for instance, m6A, ATAC-seq, RNA-seq integrated multi-
omics single cell analysis, it is possible to generate cell state probability occupancy 
distribution and ultimately identify discrete, preferred transcriptomic and epi-
transcriptomic cell state occupancies or quanta states. This will allow to construct 
an individualized transcriptomic/epitranscritomic landscape and to find patterns 
within the seemingly stochastic, chaotic environment that is the tumor.
Can we integrate multiple epigenetic “landscapes” with observed clinical out-
comes and use this information on a training predictive model to identify discrete 
favorable and unfavorable cellular microstates? And ultimately can we target 
plasticity-based processes to convert the microstate cellular make up of a highly 
malignant tumor bulk into a less aggressive cellular composition? It is plausible that 
m6A regulatory processes may represent a key target in this endeavor.
6. Conclusion
In this chapter, we introduce GBM in the context of early genetic charac-
terization and suggest that limitations in discrete classification hinted at an 
inherent cell state fluidity or plasticity. This plasticity may stand as a key func-
tion utilized by GSCs and differentiated cancer cells to rapidly and constantly 
respond to natural and non-natural/therapy induced microenvironmental 
fluctuations. Epitranscriptomic dynamic changes are explored as a new frontier 
in epigenetic based adaptation mechanisms. Additionally, single cell multi-omic 
technology and its yet to occur application to m6A can pave the way for improve-
ment in GBM characterization and patient management. Lastly, we theorize 
that the integration of multi-omic cell technology and m6A using massive, high 
dimensional patient data can aid in the characterization of plasticity through the 
identification of GBM cell states distribution and quantum state occupancy bias. 
In the future, such works can be used to develop a Waddington like epigenetic 
landscape predicting favorable cell state distribution and thus help in the devel-
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